Argenx announces vyvgart (efgartigimod alfa) authorized for sale by health canada for generalized myasthenia gravis

Amsterdam, the netherlands — sep. 2 1 , 2023—argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that health canada has issued a notice of compliance authorizing vyvgartⓇ (efgartigimod alfa) for the treatment of generalized myasthenia gravis (gmg) in adult patients who are anti-acetylcholine receptor (achr) antibody positive. with this regulatory milestone, vyvgart is the first-and-only neonatal fc receptor (fcrn) blocker authorized for sale in canada.
ARGX Ratings Summary
ARGX Quant Ranking